论文部分内容阅读
目的探讨孟鲁司特对支气管哮喘患儿血清白细胞介素-17(IL-17)的影响。方法 90例支气管哮喘患儿随机分为两组,观察组50例,对照组40例,对照组采用常规治疗,观察组在常规治疗基础上加用孟鲁司特,治疗3个月后评价疗效,测定患儿治疗前后血清IL-17的变化。结果观察组总有效率为96%,对照组总有效率为87.5%,两组比较差异有统计学意义(P<0.05)。两组治疗后均明显降低血清IL-17的表达(P<0.01),并且与对照组比较,观察组降低更明显(P<0.05)。结论孟鲁司特可以通过拮抗IL-17而改善支气管哮喘患儿病情。
Objective To investigate the effect of montelukast on serum interleukin-17 (IL-17) in children with bronchial asthma. Methods Ninety children with bronchial asthma were randomly divided into two groups: observation group (50 cases) and control group (40 cases). The control group was treated with conventional therapy. The observation group was treated with montelukast on the basis of routine treatment. The therapeutic effect was evaluated after 3 months , Measured before and after treatment in children with changes in serum IL-17. Results The total effective rate was 96% in the observation group and 87.5% in the control group. The difference between the two groups was statistically significant (P <0.05). The levels of serum IL-17 in both groups were significantly decreased after treatment (P <0.01), and compared with the control group, the reduction in the observation group was more obvious (P <0.05). Conclusion Montelukast can improve the condition of children with bronchial asthma by antagonizing IL-17.